<DOC>
	<DOC>NCT00550797</DOC>
	<brief_summary>The researchers propose to study the airways of asthmatics given TPI ASM8 for 14 days, and examine the protective effects on allergen-induced bronchoconstriction, hyperresponsiveness and airway inflammation.</brief_summary>
	<brief_title>Study to Evaluate the Safety and Efficacy TPI ASM8 in Subjects With Asthma</brief_title>
	<detailed_description>Early and late asthmatic responses were attenuated by ASM8 and by placebo solution.Methacholine challenge was not affected by study medication. Other parameters were unchanged.</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Men and women 18 to 65 years of age Intermittent mild to moderate allergic asthma as defined by ATS/ERS criteria History of episodic wheeze and shortness of breath Significant acute or chronic medical, neurologic, cardiovascular or psychiatric illness, asthma exacerbation or respiratory infection in the preceding 6 weeks Use of oral/injectable corticosteroids within the last 60 days or currently on any antiasthmatic drugs, immunosuppressives, nonsteroidal antiinflammatory drugs or anticoagulants</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Steroid-naive, non-smokers</keyword>
	<keyword>Mild to moderate allergic asthmatic adults</keyword>
</DOC>